AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01532232
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
Trial: NCT03533244
Drug: 0.1% AG-86893 Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop, three times daily to the study eye for 28 days
Trial: NCT03533244
Drug: 0.3% AG-86893 Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop, three times daily to the study eye for 28 days
Trial: NCT00612196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00273429
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00242996
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01196416
Drug: Gamma-Secretase Inhibitor RO4929097
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02484222
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
Trial: NCT00064792
Drug: Simvastatin Susp.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
Trial: NCT00064792
Drug: OraPlus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
Trial: NCT01870726
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily.
Trial: NCT00315016
Drug: eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active comparator
Trial: NCT00315016
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (double dummy)
Trial: NCT00682955
Drug: Zinc Sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg per day, Zinc Sulphate tablet has been given to subjects.
Trial: NCT00682955
Drug: Zinc Sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
Trial: NCT03430232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%
Trial: NCT03430232
Drug: STR-324 Dose Level B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long infusion of a solution for intravenous administration
Trial: NCT03430232
Drug: STR-324 Dose Level C
RxNorm normalized name: C.I. acid blue 324
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long infusion of a solution for intravenous administration
Trial: NCT03430232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%
Trial: NCT01248949
Drug: MEDI3617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
Trial: NCT02827136
Drug: hypafix
RxNorm normalized name: Dressing Hypafix 2"x10 yd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appliance of hypafix on both shoulder tip after anesthetic induction
Trial: NCT00502008
Drug: Coccinia Cordifolia (herbal extract)
RxNorm normalized name: Coccinia grandis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00527904
Drug: PN400 (VIMOVO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
Trial: NCT00527904
Drug: PN 400 (VIMOVO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
Trial: NCT03998969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet manufactured to mimic DA-5204
Trial: NCT02800083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02249039
Drug: intermittent IV CLON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
Trial: NCT00274677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment arm
Trial: NCT03778450
Drug: Analgesics, Opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are included in the long-term opioid group if they started an opioid-therapy between 2013 and 2017 and received consecutive prescriptions for opioid medications over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The treatment will be assessed using the ATC codes of opioid~treatment N02AA01, N02AA05, N02AB03, N02AE01, N02AX02, N02AX01, N02AX06) reported in reimbursed medicines to patients.
Trial: NCT03778450
Drug: Non-Opioid Analgesic
RxNorm normalized name: Non-opioid analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with non-opioid pain medication are included, if they received a medication therapy with anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants or non-opioid analgesics (NSAIDs, Metamizole) over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The non-opioid treatment will be assessed using the ATC codes (N03AX12, N03AX16, N03AF01) of treatment reported in reimbursed medicines to patients.
Trial: NCT02451462
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02384512
Drug: Azilect®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZILECT® 1mg Tablets
Trial: NCT01336153
Drug: MLC601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
Trial: NCT01336153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
Trial: NCT00121186
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m\^2 on days 1, 3, and 7 post-transplant.
Trial: NCT04678388
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Cap., single oral administration under fasting condition
Trial: NCT04678388
Drug: Test drug 1
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Tab., single oral administration under fasting condition
Trial: NCT04678388
Drug: Test drug 2
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Tab., single oral administration under fasting condition
Trial: NCT01313650
Drug: 62.5/25mcg
RxNorm normalized name: TRELEGY ELLIPTA 100/62.5/25MCG INH 14D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719/GW64244
Trial: NCT01357252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02857998
Drug: HMPL-523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, once daily
Trial: NCT00376454
Drug: GW493838
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04014361
Drug: LY3154885 - Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04014361
Drug: Placebo - Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00345618
Drug: Idrabiotaparinux sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection
Trial: NCT00345618
Drug: Placebo (for idrabiotaparinux sodium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL pre-filled syringe~Subcutaneous injection
Trial: NCT00345618
Drug: Placebo (for warfarin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin matching capsules~Oral administration
Trial: NCT01737216
Drug: Zoledronic acid plus EP/TP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
Trial: NCT01737216
Drug: EP/TP
RxNorm normalized name: Ethinylestradiol/Testosterone Propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
Trial: NCT04014361
Drug: LY3154885 - Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03049735
Drug: Estradiol/norethindrone acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
Trial: NCT02283645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03171831
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide（50 mg/kg/day,4 days）
Trial: NCT03171831
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）
Trial: NCT01794260
Drug: Cream from Zingiber cassumunar Roxb. extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01794260
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00970229
Drug: [123I]MNI-420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not \> 10% of 8 mCi limit)of \[123I\]MNI-420, followed by SPECT imaging.
Trial: NCT01052077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01052077
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02790580
Drug: Dose-dense doxorubicin/cyclophosphamide + sunitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease.
Trial: NCT02790580
Drug: Dose-dense doxorubicin/cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease.
Trial: NCT03230526
Drug: [18F]DPA-714 PET scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One PET scan using \[18F\]DPA-714 is done at M2 between two \[123I\]FP-CIT scan (DaTscan) done at M1 and M23.~Neuropsychological assessment is done at M0, M18 and M24
Trial: NCT00217711
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine
Trial: NCT02823808
Drug: NESINA ACT TAB. 25/15mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
Trial: NCT02823808
Drug: AMARYL-M TAB. 2/500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
Trial: NCT00132223
Drug: Contrast agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01725594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03624595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
Trial: NCT00912457
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 1 p/day for 28 days
Trial: NCT00289926
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
Trial: NCT04038853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical to the study intervention drug
Trial: NCT00903656
Drug: doxorubicinhydrochloride, Lapatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
Trial: NCT01474863
Drug: High Dose Citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial intravenous bolus of 20mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9mg/kg (max 700mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days
Trial: NCT01474863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D5W IV fluids at isovolumetric rate (about 15ml/hr)
Trial: NCT01474863
Drug: Low Dose Citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial intravenous bolus of 10mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 4.5mg/kg (max 350mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days.
Trial: NCT01234194
Drug: rising remifentanil concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil effect-compartment concentrations 0,1,2,3 ng/ml
Trial: NCT01234194
Drug: falling remifentanil concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml
Trial: NCT03286205
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron infusion based on weekly or every 3 week dosage.
Trial: NCT03231943
Drug: GSK3640254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.
Trial: NCT03231943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.
Trial: NCT00708175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
Trial: NCT00985322
Drug: non-RAS inhibitor antihypertensive therapy
RxNorm normalized name: MAO inhibitors, antihypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood Pressure lowering regimen not including RAS inhibitors
Trial: NCT02810899
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
Trial: NCT02487030
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily
Trial: NCT01685424
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per routine clinical practice in the United Kingdom
Trial: NCT03770624
Drug: QL-007 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL-007 will be administered orally daily over the 28 days under fasted state.
Trial: NCT02488889
Drug: placebo beverage (for alcohol)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01729871
Drug: uninterrupted vitamin K antagonist (VKA)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
Trial: NCT00718692
Drug: Sym001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cohort will receive one single dose of Sym001 according the assigned dose level.
Trial: NCT03176563
Drug: Placebo to Arctuvan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application of Placebo to Arctuvan in the clinical trial REGATTA (NCT03151603)
Trial: NCT00857857
Drug: GW870086X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product
Trial: NCT00160381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral Daily for 12 months
Trial: NCT00857857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control
Trial: NCT03180125
Drug: Corticosteroid and 1%lidocain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection in the carpal tunnel
Trial: NCT03530280
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The preoperative placebo oral tablet and the postoperative sham block will perform.
Trial: NCT03977493
Drug: Placebo - Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection in each muscle.
Trial: NCT00050947
Drug: oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03222401
Drug: 1 mg/kg single infusion of F598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg single infusion of F598
Trial: NCT03222401
Drug: 3 mg/kg single infusion of F598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg single infusion of F598
Trial: NCT03222401
Drug: 10 mg/kg single infusion of F598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg single infusion of F598
Trial: NCT01279681
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01279681
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01279681
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00741442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo.
Trial: NCT00338923
Drug: HO/03/03
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03217994
Drug: gel HP
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel of hygrogen peroxide for teeth bleaching
Trial: NCT01043991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no